The Food and Drug Administration has approved a pioneering gene therapy for a rare form of childhood blindness, the Washington Post reports.
Gene therapy has experienced many setbacks in recent years, and even successful treatments will probably be impossibly expensive.
Philadelphia-based Spark Therapeutics, which makes the blindness treatment, will not announce the price until January, but analysts speculate it could be as much as $1 million for both eyes.
The blindness therapy, known as Luxturna, involves injecting copies of the normal version of a gene called RPE65 into a patient's eye. RPE65 is responsible for producing a protein that makes light receptors work. The mutated gene causes inherited retinal diseases affecting about 1,000 to 2,000 people in the United States.
Read the full story: